

Biovotion acquires Solianis' sensor infrastructure

21st October 2011

1 Sensor acquisition

Today Biovotion has finalised the acquisition of the Solianis sensors and their related relevant technical infrastructure.

This acquisition presents new business opportunities when combined with the recent acquisition of the entire Solianis IP portfolio. The full availability of IP and technology will allow Biovotion to continue unfolding its activities within the field of physiological monitoring.

2 New Business opportunities

Thanks to the latest acquisitions, Biovotion can now directly extend the range of applications and its technology platform.

The availability of this IP portfolio and the respective sensors allows Biovotion to consider expanding the physiological monitoring platform. Biovotion can also directly benefit from previously established technology and know-how combined with the now readily available sensor technology and software.

Within the scientific and engineering fields, Biovotion covers areas such as biophysics, dielectrics, optics, software, evaluation of complex data or physiological processes and their biophysical implications.

Within the market/application fields, this includes expertise on the development of highly portable wearable devices, their respective regulatory requirements, sophisticated technical ICT environments, design, set up and execution of experiment/clinical studies.

This involves state of the art infrastructures in cooperation with highly respected clinical partners.

3 Biovotion's VSM platform

In a first step, Biovotion is working on a vital sign monitoring (VSM) application for non-invasive physiological monitoring of blood circulation parameters. Biovotion's VSM platform will be highly portable and can be easily worn to enable continuous monitoring of various global and local vital sign parameters.



<u>Global:</u> Heart rate, arterial blood oxygenation, respiration rate, motion activity <u>Local:</u> Cutaneous blood volume/perfusion, venous blood oxygenation, skin temperature

4 Contact

For further information please contact either

Dr. Andreas Caduff, CEO andreas.caduff@biovotion.com Phone +41 44 515 61 71 Mobile +41 79 677 41 79

or

Dr. Mark Talary, CTO mark.talary@biovotion.com Phone +41 44 515 61 72 Mobile +41 76 582 41 50

To keep you informed, we invite you to visit our website (<u>www.biovotion.com</u>) and find up to date information in the community news section.